利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

65 条记录 (耗时 0.031 秒)

    USE OF NUCLEOLIN AS A BIOMARKER FOR LYMPHANGIOGENESIS IN CANCER PROGNOSIS AND THERAPY
    2.
    发明申请
    USE OF NUCLEOLIN AS A BIOMARKER FOR LYMPHANGIOGENESIS IN CANCER PROGNOSIS AND THERAPY 审中-公开
    作为生物标记物的核蛋白用于癌症预防和治疗中的淋巴细胞生成

    公开(公告)号：US20130023479A1

    公开(公告)日：2013-01-24

    申请号：US13554913

    申请日：2012-07-20

    申请人： Yongzhang Luo ,  Wei Zhuo ,  Yan Fu ,  Guodong Chang

    发明人： Yongzhang Luo ,  Wei Zhuo ,  Yan Fu ,  Guodong Chang

    IPC分类号： G01N33/574 ,  A61K38/17 ,  A61P35/04 ,  C40B30/04

    CPC分类号： G01N33/574 ,  A61K38/39 ,  C07K16/28 ,  C07K2317/76 ,  G01N2333/515 ,  G01N2800/52 ,  G01N2800/56 ,  G01N2800/7014

    摘要： The present invention relates to a method of identifying cancer subjects, in particular human patients, who are suitable for anti-lymphangiogenesis therapy to prevent tumor growth and tumor metastasis. The present invention also relates to a new approach, which uses nucleolin as a bait to search and screen for lymphangiogenesis inhibitors or cancer suppressors, which function in a manner that is analogous to endostatin. The invention is based upon the discovery that nucleolin is specifically expressed on lymphangiogenic vessels and functions as a specific receptor for endostatin, and thus is involved in the signal transduction pathway of endostatin as an anti-lymphangiogenesis inhibitor. The present invention also discloses that cell surface nucleolin on lymphatic endothelial cells is a biomarker for lymphangiogenic vessels, which could be used for the prediction of tumor metastasis.

    摘要翻译： 本发明涉及鉴定适合于抗淋巴管生成治疗以预防肿瘤生长和肿瘤转移的癌症受试者，特别是人类患者的方法。 本发明还涉及使用核仁林作为诱饵来搜索和筛选淋巴管生成抑制剂或癌抑制因子的新方法，其以类似于内皮抑素的方式起作用。 本发明基于以下发现：核仁林在淋巴管生成血管上特异性表达，并且作为内皮抑制素的特异性受体起作用，因此参与作为抗淋巴管生成抑制剂的内皮抑素的信号转导途径。 本发明还公开了淋巴管内皮细胞上的细胞表面核仁素是淋巴管生成血管生物标志物，可用于预测肿瘤转移。

    CONJUGATE COMPRISING ANGIOSTATION OR ITS FRAGMENT, THE METHOD FOR PRODUCING THE CONJUGATE AND USE THEREOF
    3.
    发明申请
    CONJUGATE COMPRISING ANGIOSTATION OR ITS FRAGMENT, THE METHOD FOR PRODUCING THE CONJUGATE AND USE THEREOF 审中-公开
    包含放射性物质或其碎片的方法，其生产方法和使用方法

    公开(公告)号：US20100184661A1

    公开(公告)日：2010-07-22

    申请号：US12522661

    申请日：2008-01-10

    申请人： Yongzhang Luo ,  Guodong Chang ,  Shuling Yang ,  Lei Gao ,  Yan Fu

    发明人： Yongzhang Luo ,  Guodong Chang ,  Shuling Yang ,  Lei Gao ,  Yan Fu

    IPC分类号： A61K38/17 ,  C07K17/08 ,  A61P35/00 ,  C07K1/00

    CPC分类号： A61K47/60 ,  C12N9/6435 ,  C12Y304/21007

    摘要： The present invention provides an anti-tumor or anti-angiogenesis medicament, the combination or kit containing the medicament, and the method for producing the same. The anti-tumor or anti-angiogenesis medicament contains a conjugate comprising a modifying agent and the angiostatin or its fragments, wherein the conjugate exhibits prolonged in vivo half-life as compared to an unmodified angiostatin or its fragments. The modifying agent is selected from the group consisting of macromolecular polymers, protein molecules or fragments thereof, peptides, small molecules, or chemical substances of any other forms.

    摘要翻译： 本发明提供抗肿瘤或抗血管生成药物，含有该药物的组合物或试剂盒及其制备方法。 抗肿瘤或抗血管生成药物含有包含修饰剂和血管抑素或其片段的缀合物，其中与未修饰的血管抑素或其片段相比，缀合物表现出延长的体内半衰期。 改性剂选自高分子聚合物，蛋白质分子或其片段，肽，小分子或任何其它形式的化学物质。

    CONJUGATE ANGIOSTATION OR ITS FRAGMENT, THE METHOD OF PRODUCING THE CONJUGATE AND USE THEREOF
    10.
    发明申请
    CONJUGATE ANGIOSTATION OR ITS FRAGMENT, THE METHOD OF PRODUCING THE CONJUGATE AND USE THEREOF 审中-公开
    联合攻击或其碎片，生产和使用它们的方法

    公开(公告)号：US20140056966A1

    公开(公告)日：2014-02-27

    申请号：US13488932

    申请日：2012-06-05

    申请人： Yongzhang LUO ,  Guodong Chang ,  Shuling Yang ,  Lei Gao ,  Yan Fu

    发明人： Yongzhang LUO ,  Guodong Chang ,  Shuling Yang ,  Lei Gao ,  Yan Fu

    IPC分类号： A61K47/48

    CPC分类号： A61K47/60 ,  C12N9/6435 ,  C12Y304/21007

    摘要： The present invention provides an anti-tumor or anti-angiogenesis medicament, the combination or kit containing the medicament, and the method for producing the same. The anti-tumor or anti-angiogenesis medicament contains a conjugate comprising a modifying agent and the angiostatin or its fragments, wherein the conjugate exhibits prolonged in vivo half-life as compared to an unmodified angiostatin or its fragments. The modifying agent is selected from the group consisting of macromolecular polymers, protein molecules or fragments thereof, peptides, small molecules, or chemical substances of any other forms.

    摘要翻译： 本发明提供抗肿瘤或抗血管生成药物，含有该药物的组合物或试剂盒及其制备方法。 抗肿瘤或抗血管生成药物含有包含修饰剂和血管抑素或其片段的缀合物，其中与未修饰的血管抑素或其片段相比，缀合物表现出延长的体内半衰期。 改性剂选自高分子聚合物，蛋白质分子或其片段，肽，小分子或任何其它形式的化学物质。